An Australian stem cell and regenerative medicine company
March 05, 2024
Cynata Therapeutics treats first patient in aGvHD clinical trial
In early March, the first patient was enrolled and treated in Cynata’s Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).